Corporate Magazine 2012 - Boehringer Ingelheim

Rapid progress in global healthcare generatesdemand for innovative medicines.MARKET ACCESS FORNEW MEDICINESRapid progress in global healthcare systems today continuouslygenerates demand for urgently needed innovative medicines. However,in many cases, innovations in medicines and technology result inincreased healthcare expenditure, at least in the short term. Healthcarebudgets are under severe pressure and cost-consciousness amonghealthcare providers has increased.BENEFIT FOR PATIENTSAND SOCIETYWe at Boehringer Ingelheim areconvinced that our new andinnovative products offer significantadditional medical benefitto patients and economic benefitto society.The market access environment formedications has changed structurally,driven by the limited affordability ofhealthcare for the public health sectorin growing and aging societies. Theimpact on the pharmaceutical industryis that the regulatory requirements,such as demonstrating efficacy, safetyand quality of products, are no longersufficient when bringing new medicinesto the market. Additionally, medicaland economic benefit have to be demonstratedwhen new medicines arebrought to the market.Innovation – risk-adequate incentivesBoehringer Ingelheim is guided by theaspiration to provide a sustainable contributionto the improvement of thehealth of society with innovative medications.As a research-driven company,we can, however, only continue to investin our own research and developmentof innovative medications, if weare risk-adequate incentivised and rewardedfor our entrepreneurial risk andinnovation. Cost-benefit calculations ofthe public sector for sole cost controlare falling short related to the sustainedimprovement of public health.Our market access organisationsTo find a solution for the divergent goalsof society and Boehringer Ingelheim,we have built up corporate and localmarket access structures and processes,which have helped to achieve and sustainaccess and reimbursement of ourproducts in most markets.However, market access activities forour two new innovative products,pradaxa® and trajenta®, have identi-84Boehringer Ingelheim annual report 2012